NPS Medicinewise says the PBAC
approval of Pradaxa, Xarelto and
Eliquis (PD yesterday) means health
professionals should weigh the risks
and benefits of switching to these
oral anticoagulants.
NPS ceo Lynn Weekes said that
while the subsidy of the newer
products offers greater choice for
GPs and their patients, evidence
suggests people with non-valvular
AF whose anticoagulation is well
controlled using warfarin may not
benefit clinically from switching.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Apr 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.